TFCP2 and hepatocellular carcinoma: As an orthogonal approach to confirm these findings, we took advantage of a previously published pharmacological inhibitor of TFCP2, factor quinolinone inhibitor 1 (FQI1) (Fig. S4A), which was shown to specifically block TFCP2 DNA binding activity and inhibited tumor growth in hepatocellular carcinoma mouse xenografts (21).